Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

NCT ID: NCT03050086

Last Updated: 2019-01-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-03-29
• Study Completion Date: 2018-06-19

Brief Summary

An open label feasibility study using BPX-04 topical minocycline gel in papulopustular rosacea.

Conditions

Moderate to Severe Papulopustular Rosacea

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BPX-04 1% Minocycline Topical Gel

once daily topical administration of 1% minocycline gel to the face

Group Type: EXPERIMENTAL

BPX-04 1% minocycline topical gel

Intervention Type: DRUG

once daily administration of topical minocycline gel to face

BPX-04 2% Minocycline Topical Gel

once daily topical administration of 2% minocycline gel to the face

Group Type: EXPERIMENTAL

BPX-04 2% minocycline topical gel

Intervention Type: DRUG

once daily administration of topical minocycline gel to face

BPX-01 Vehicle Topical Gel

once daily topical administration of vehicle gel to the face

Group Type: PLACEBO_COMPARATOR

BPX-04 vehicle topical gel

Intervention Type: DRUG

once daily administration of topical minocycline gel to face

Interventions

BPX-04 1% minocycline topical gel

once daily administration of topical minocycline gel to face

Intervention Type: DRUG

BPX-04 2% minocycline topical gel

once daily administration of topical minocycline gel to face

Intervention Type: DRUG

BPX-04 vehicle topical gel

once daily administration of topical minocycline gel to face

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female subjects ≥18 years of age at the time of consent.

2. Subjects do not have any medical conditions, other than rosacea, that in the opinion of the investigator, put the subject at unacceptable risk or could interfere with study assessments or integrity of the data.

3. A clinical diagnosis of moderate to severe (Grade 3 or 4) facial rosacea (papulopustular (Subtype 2) or mixed erythematotelangiectatic (Subtype 1) and papulopustular (Subtype 2)) as determined by the Investigator's Global Assessment (IGA) at Visit 1/Screening.

4. Female subjects of childbearing potential (including pre-puberty) are willing to use effective contraceptive method for at least 28 days before baseline (Day 0) and at least 28 days after the last study product administration or have a sterilized or same-sex partner for the duration of the study. Hormonal contraceptives must be on a stable dose for at least 12 weeks before baseline (Day 0). Subjects using low dose oral contraceptives must use a second form of birth control (e.g., barrier method such as condoms with spermicide).

Note: Female subjects of non-childbearing potential are defined as follows:

1. Female subjects who have had surgical sterilization (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation);

2. Female subjects who have had a cessation of menses for at least 12 months and a follicle-stimulating hormone (FSH) test confirming non-childbearing potential (refer to the central laboratory reference range for menopausal women) or cessation of menses for at least 24 months without FSH levels confirmed;

5. Female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline (Day 0).

6. Treatment with hormonal therapy must be on a stable dose and frequency for at least 12 weeks before baseline (Day 0) and must remain stable throughout the study.

7. Subjects who use make-up, facial moisturizers, creams, lotions, cleansers and/or sunscreens must have used the same product brands/types for a minimum period of 14 days prior to baseline (Day 0), must agree not to change brand/type or frequency of use throughout the study and must agree not to use make-up, facial moisturizers, creams, lotions, cleansers and/or sunscreens on the clinic visit days before the visit.

8. Subjects must be capable of giving informed consent and the written informed consent must be obtained prior to any study-related procedures.

Exclusion Criteria

1. Have a history of skin disease, presence of skin condition or excessive facial hair the PI believes would interfere with the study

2. Have moderate or severe rhinophyma, severe telangiectasia or plaque-like facial edema

3. Have rosacea conglobata or fulminans, corticosteroid induced rosacea or facial erythrosis other than rosacea

4. Have ocular rosacea of a severity that requires systemic treatment

5. Have a history of any adverse reaction to minocycline or other tetracycline class antibiotic

6. Have a clinically significant chemistry or hematology value at baseline or have an ALT or AST at screening that is greater than or equal to 2x normal

7. Have conditions or factors that the PI believes may affect the response of the skin or the interpretation of the results

8. Participated in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies

9. Have used on the face an OTC topical medication for the treatment of rosacea within 4 weeks prior to baseline.

10. Have used prescription topical (on the face) or oral antibiotics or corticosteroids within 4 weeks prior to baseline.

11. Have had a facial procedure such as chemical peel, laser, microdermabrasion within 8 weeks prior to baseline

12. Have received photodynamic therapy or phototherapy with blue or red light within 12 weeks prior to baseline

13. Have used an oral retinoid within 6 months or a topical retinoid within 3 months prior to baseline

14. Current drug or alcohol abuse

15. Female subject who is breastfeeding, pregnant or who is planning a pregnancy during the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BioPharmX, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

AnnaMarie Daniels

Role: STUDY_DIRECTOR

BioPharmX, Inc.

Locations

Study Center

San Diego, California, United States

Countries

United States

Other Identifiers

BPX-01-C05

Identifier Type: -

Identifier Source: org_study_id